Personalised targeted immunomodulation in patients with ARDS related to COVID19 and future pandemic pathogens (COMODULATE-project)

Goal Seriously ill corona patients receive anti-inflammatory medication in the hospital to control the immune response of their immune system. There are a number of medications for this, with different mechanisms of action and costs. During the corona pandemic, many corona patients received multiple anti-inflammatory medications, while in some patients certain specific and expensive medications proved to be less effective due to differences in immune responses. This project aims to gain knowledge about immune responses. Research design By looking back at a database with blood and saliva samples taken from corona patients, we want to investigate whether we can properly distinguish immune responses with a blood test at the bedside in the future. We also want to investigate whether there are substances in the blood and saliva that give rise to more targeted treatment. This knowledge about differences in immune responses and medication may also be applicable to subsequent pandemics not caused by the coronavirus. Executive parties Amsterdam UMC, Erasmus MC, Leiden University Medical Center (LUMC), Reinier de Graaf Gasthuis and Antonius Hospital. Context This research is one of the studies in the field of research into optimal medical specialist care for COVID-19. The aim of the studies is to answer important knowledge gaps in the field of treatment. ZonMw facilitates these studies in the COVID-19 Treatment sub-programme to contribute to promoting optimal care for COVID-19. The knowledge gaps have been identified by the Multidisciplinary COVID-19 Science Committee of the Federation of Medical Specialists (FMS). More information Main applicant: Dr. H. Endeman (Erasmus MC) Project leader and secretary: Dr. L. Bos (Amsterdam UMC)